[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vision-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vision-disorders":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,57,83,114,152,179],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100564284","phase-2-study-to-evaluate-ultevursen-in-subjects-with-retinitis-pigmentosa-rp-due-to-mutations-in-exon-13-of-the-ush2a-gene-100564284",false,"NCT06627179","Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene","A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene","LUNA","Inclusion Criteria:\n\n1. An adult (≥18 years) willing and able to provide informed consent for participation prior to performing any study related procedures\n2. OR A minor (8 to \\\u003C18 years) able to provide age-appropriate assent for study participation with a parent or legal guardian willing and able to provide written permission for the subject's participation prior to performing any study related procedures. An adult willing to comply with the protocol, follow study instructions, attend study visits as required and willing and able to complete all study assessments, in the opinion of the Investigator.\n\n   OR A minor able to complete all study assessments and comply with the protocol and has a parent or caregiver willing and able to follow study instructions and attend study visits with the subject as required, in the opinion of the Investigator.\n3. Both eyes exhibit clinical presentation consistent with RP involving Usher syndrome type 2 or NSRP based on ophthalmic, audiologic, or vestibular examinations. At screening, the Investigator will make the clinical diagnosis of \"Usher syndrome type 2a,\" defined as RP with congenital hearing loss, or \"non-syndromic RP,\" defined as RP without congenital hearing loss.\n4. A molecular diagnosis of biallelic disease causing variants (pathogenic or likely pathogenic) in the USH2A gene where at least one of the variants is located on exon 13. A historic genotyping report from a certified laboratory is acceptable with Sponsor approval.\n5. Clearly visible and measurable SD-OCT horizontal EZ width of ≥2.2 mm in both eyes based on the assessment of the CRC.\n6. BCVA ≥55 letters based on ETDRS (equivalent to 20\u002F80 based on Snellen notation, or logarithm of the minimum angle of resolution \\[logMAR\\] +0.6) in both eyes.\n7. Impairment of VF as assessed by SP with a mean sensitivity greater than 4 decibels (dB) and less than 25 dB measured by a V target size in the TE at screening.\n8. Mean sensitivity greater than 2 dB as determined by MP in the TE at screening.\n9. Symmetry of baseline disease in both eyes, defined as the mean BCVA (based on ETDRS) of one eye within ≤10 letters of the mean BCVA of the other eye at screening.\n\nExclusion Criteria:\n\n1. Presence of additional non-exon 13 USH2A pathogenic or likely pathogenic variant on the USH2A allele carrying the exon 13 mutation in subjects who have one exon 13 disease causing variant and one non-exon 13 disease causing variant.\n2. Presence of additional non-exon 13 USH2A pathogenic mutation(s) on both USH2A alleles in subjects who have biallelic exon 13 mutations.\n3. Presence of pathogenic or likely pathogenic variants in genes (other than the USH2A gene) which are known to be associated with other inherited retinal degenerative diseases or syndromes. Specifically, the presence of homozygous or compound heterozygous known disease-causing mutations in other genes involved in recessive retinal dystrophies, or the confirmed presence of a known single disease-causing variant in genes involved in dominant, X-linked, or mitochondrial retinal dystrophy genes is exclusionary.\n4. At screening, the EZ horizontal or vertical width are outside the field of the SD-OCT scan based on the assessment of the CRC.\n5. Presence of any significant ocular or non-ocular disease\u002Fdisorder (including medication and laboratory test abnormalities) which, in the opinion of the Investigator may either put the subject at risk because of participation in the study, may impact the subject's ability to participate in the study, or may interfere with assessment of efficacy and safety in the study.\n6. Presence of unstable concurrent cystoid macular edema (CME), or subject started on (or changed dose of) any medication for CME in the 3 months prior to enrollment. CME is allowed if stable for 3 months (with or without treatment). However, stable CME that disrupts the EZ width measurement, as determined by CRC, is an exclusion.\n7. Any intraocular surgery within 3 months of study entry or any planned intraocular or peri-ocular surgery during the study. Subjects may be eligible after 3 months post-surgery as long as they have fully recovered, in the opinion of the Investigator.\n8. Receipt of any IVT injection prior to study entry.","ALL","8 Years",{"count":20,"type":21},81,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. This is a multicenter Double-masked, Randomized, Sham-controlled study which will enroll 81 subjects.",[27,28,29,30,31,32,33],"Retinitis Pigmentosa (RP)","Usher Syndrome Type 2","Deaf Blind","Retinal Disease","Eye Diseases, Hereditary","Eye Disorders Congenital","Vision Disorders",[35,28,29,36,37,38,39,40,41,15,42,43],"Retinitis Pigmentosa","USH2A","RP","Exon 13","RNA therapies","antisense oligonucleotide","exon skipping","IVT","NSRP","RECRUITING","2026-06-16",{"date":47,"type":48},"2026-06-18","ACTUAL",{"date":50,"type":48},"2024-12-11",{"date":52,"type":21},"2027-12",{"name":54,"class":55},"Laboratoires Thea","INDUSTRY",28,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":22,"phases":68,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100523667","effect-of-carotenoids-supplementation-on-visual-function-in-chinese-subjects-100523667","NCT06098677","Effect of Carotenoids Supplementation on Visual Function in Chinese Subjects","Effect of Carotenoids Supplementation on Visual Function in Chinese Subjects Free of Retinal Disease: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Chinese subjects\n* Age 35 years or above\n* Monocular BCVA of 6\u002F6 or better\n* No more than +\u002F- 5 diopters spherical equivalence of refraction\n* No previous consumption of supplements containing macular carotenoids (L, Z and\u002For MZ) within the last 12 months\n* Without severe retinal diseases (eg. retinal detachment, glaucoma, macular hole, idiopathic epiretinal membrane, retinitis pigmentosa, and age-related macular degeneration (assessed by experienced ophthalmologists during ocular examination)\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* With diagnosed diabetes\n* With severe systemic disease which affects physical mobility and successful follow-up\n* Contrast sensitivity at a spatial density of 6 cpd ≤ 1.5 % at baseline in the eye with better visual acuity\n* Subjects who plan to receive cataract surgery within the next year\n* Subjects who are unable to cooperate with the examinations during follow-ups, such as those who suffer from other serious systemic diseases or mental abnormalities\n* History of intraocular surgery (eg. cataract surgery, vitrectomy and retinal laser photocoagulation)",true,"35 Years",{"count":67,"type":21},220,[69],"NA","The macula is a pigmented area at the center of the retina, and responsible for the central, high-resolution color vision. Age-related macular degeneration (AMD) is a disease of the macula and is the leading cause of irreversible vision impairment and blindness worldwide. The yellow pigment at the macula is referred to as macular pigment. There is now strong evidence showing that macular pigment (MP), which is composed of the dietary carotenoids lutein (L), meso-zeaxanthin (MZ), and zeaxanthin (Z) is protective against AMD and vision loss. MP is a powerful antioxidant and also filters short-wavelength (blue) light at the macula. The AREDS2 study concluded that supplementation of L and Z is beneficial for patients with non-advanced age-related macular degeneration (AMD). The CREST and other studies had reported that dietary supplementation of these carotenoids could enhance contrast sensitivity among the Caucasian population, whereas little information is known about the effect of dietary supplementation of carotenoids on contrast sensitivity among Chinese. Thus in this study, we aim to investigate whether supplementation of a formulation containing 10 mg L, 10 mg MZ, and 2mg Z on contrast sensitivity in Chinese subjects free of retinal disease. This study is a single-center, double-blinded, placebo-controlled, randomized clinical trial conducted at Zhongshan Ophthalmic Center (ZOC), Sun Yat-sen University, Guangzhou, China. Participants in the intervention group received oral supplementation of 10 mg L, 10 mg MZ, and 2mg Z in a formula base oil suspension as one soft gel capsule in the morning per day. Participants in the control group receive one soft gel capsule of placebo oil per day. The intervention and placebo supplements are identical in external appearance, and the two treatments are therefore indistinguishable from each other. The duration of the study intervention is 12 months, and study visits are conducted at baseline, 3 months, 6 months, and 12 months. The primary outcome measure is the change in contrast sensitivity (CS) at 6 cycles per degree (cpd) over the study course: Y=CS4-CS1, where CS1 is CS at 6 cpd at baseline, CS4 is the CS at 6cpd at the 12-month follow-up. The secondary outcomes of this study include CS at other cpds and at other study visits, best-corrected visual acuity, subjective visual function, and skin carotenoid levels at each study visit.",[33],"NOT_YET_RECRUITING","2026-01-21",{"date":75,"type":48},"2026-01-23",{"date":77,"type":21},"2026-05-01",{"date":79,"type":21},"2027-12-31",{"name":81,"class":82},"Zhongshan Ophthalmic Center, Sun Yat-sen University","OTHER",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":64,"sex":17,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100485366","viewing-strategy-training-in-children-with-cerebral-visual-impairment-100485366","NCT05600140","Viewing Strategy Training in Children With (Cerebral) Visual Impairment","Viewing Strategy Training in Children With (Cerebral) Visual Impairment: From Spontaneous Eye Movements to a Structured Viewing Strategy","Inclusion criteria typically developing children with normal vision:\n\n* Age 5-12 years\n* linear distant visual acuity of 0.1 logMAR or better\n* Verbal IQ above 70\n* Absence of developmental disorders or psychiatric problems like ASS or AD(H)D\n\nInclusion criteria for children with ocular visual impairment:\n\n* Age 5-12 years\n* Children with linear distance visual acuity better \\\u003C=1.3logMAR and \\>0.1 logMAR\n* Intact central visual field (at least \\> 30 degrees)\n* Children with a verbal IQ above 70\n* Absence of developmental disorders or psychiatric problems like ASS or AD(H)D\n\nInclusion criteria for children with cerebral visual impairment:\n\n* Age 5-12 years\n* Linear distance visual acuity \\\u003C=0.3 logMAR\n* Having the diagnosis CVI (verified by ophthalmologists)\n* Children with a verbal IQ above 70\n* Absence of psychiatric problems like ASS or AD(H)D\n\nAdditional inclusion criterion for study 2 (evaluating training effectiveness): children with (cerebral) visual impairment should have an indication for viewing strategy training. Training should not be indicated if children have no problems performing academic tasks (i.e. when speed and accuracy of visual processing is within the normal range). The age range for study 2 is 5-9 years.\n\nExclusion criteria:\n\n* Children with VI: linear near visual acuity \\>1.0 logMAR\n* Children with visual field defect \\\u003C 30 degrees\n* Children with a verbal IQ below 70\n* Children who attended a form of vision training in the past two years\n* Children with psychiatric problems like ASS or AD(H)D\n* Auditory impairment or language impairments\n* Major life events during training","5 Years","12 Years",{"count":93,"type":21},60,[69],"Viewing strategies are strategies used to process visual Information. Many children with visual impairment seem to lack systematic viewing strategies. However, it is unknown how viewing strategies differ between children with normal vision and children with (cerebral) visual impairment. In addition, viewing strategy training is often adopted in clinical practice, but till date there is no scientific evidence about effectiveness of this approach.\n\nThe current project has two goals: (1) to measure viewing strategies used by children with normal vision, children with ocular visual impairment and children with CVI, and (2) to evaluate whether training viewing strategies results in more efficiënt visual Information processing.",[33,97],"Vision, Low",[99,100,101,102,103],"viewing strategies","(cerebral) visual impairment","visual rehabilitation","reading strategies","visual search strategies","2026-01-05",{"date":106,"type":48},"2026-01-07",{"date":108,"type":48},"2024-10-25",{"date":110,"type":21},"2026-12",{"name":112,"class":82},"Royal Dutch Visio",1,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":64,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":125,"conditions":126,"keywords":136,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":113},"100599518","natural-history-study-of-inherited-retinal-diseases-100599518","NCT07085533","Natural History Study of Inherited Retinal Diseases","Color Vision Loss Progression in IRD Patients: Retinal Structural Changes Correlations, and a Novel Color Discrimination Test for Extreme Low Vision Patients","MojiLVCDT","Inclusion Criteria:\n\n1. Color Perception and Communication Ability Participants must have the ability to verbally identify or describe colors and test stimuli. This requires adequate cognitive and communicative capacity to understand instructions and respond appropriately during color vision testing.\n2. Diagnosis of Inherited Retinal Dystrophy (IRD Group Only) Participants assigned to the IRD group must have a confirmed clinical diagnosis of an inherited retinal dystrophy\n3. No Evidence of Inherited Retinal Disease (Control Group Only)\n\nParticipants in the control group must have:\n\n* No known history or clinical evidence of inherited retinal degeneration\n* Normal retinal health or only non-retinal ocular conditions not affecting retinal function (e.g., mild cataract, corrected refractive error)\n* Normal or expected-normal color vision\n\nExclusion Criteria:\n\n1. Non retinal causes of color vision loss\n\n   * Optic neuropathies (e.g., optic neuritis, glaucoma related optic nerve damage)\n   * Cortical vision impairments affecting color perception\n   * Any other neurological or optic nerve pathology causing color vision deficiency\n2. Psychological or cognitive conditions affecting color perception or communication\n\n   * Severe developmental delays\n   * Cognitive impairments interfering with ability to comprehend or reliably perform color vision tests\n   * Psychiatric conditions that impair visual interpretation or reliable testing\n3. Prior treatment with potential transient effects on the retina\n\n   * Recent retinal surgery\n   * Recent drug therapy affecting retinal structure or function\n   * Any acute intervention that might confound the correlation analyses due to lack of a stable baseline",{"count":123,"type":21},200,"OBSERVATIONAL","This prospective, observational investigation seeks to delineate the interplay between chromatic vision deficits and both functional visual outcomes and anatomical retinal biomarkers in individuals affected by Inherited Retinal Dystrophies (IRDs). The study will recruit approximately 200 subjects, encompassing a heterogeneous population of IRD patients-spanning a range of genotypes and clinical severities-as well as control participants devoid of retinal pathology. All enrolled individuals will undergo a standardized battery of evaluations, including quantitative color vision assessment, best-corrected visual acuity (BCVA) determination, and advanced multimodal retinal imaging.\n\nThe principal aim is to characterize the relationship between impairments in color discrimination and morphologic disruptions within the outer retinal layers, with particular emphasis on the continuity and reflectivity of the ellipsoid zone (EZ)-historically referred to as the inner segment\u002Fouter segment (IS\u002FOS) junction-assessed through spectral-domain optical coherence tomography (SD-OCT). Further, the study will explore associations between chromatic perceptual deficits and underlying genetic mutations, mutation patterns specific to IRD subtypes, and the influence of patient age on the severity and progression of color vision loss.\n\nA key secondary objective is the clinical appraisal and validation of a novel diagnostic modality, the Moji Low-Vision Color Discrimination Test (Moji Test), which is specifically engineered to quantify residual color perception in individuals with advanced central visual impairment. The test's discriminatory capacity will be benchmarked against established color vision testing paradigms to assess its reliability, clinical sensitivity, and suitability for implementation in populations with severe visual acuity reduction.\n\nBy incorporating a genetically and phenotypically diverse IRD cohort, the study is designed to enable granular, stratified analyses that will refine the understanding of structural-functional correlations in hereditary retinal disease. The inclusion of a control group with preserved retinal architecture and normal color vision function will provide essential normative baselines for comparative evaluation and statistical inference.",[127,128,33,129,130,131,132,133,134,135],"Retinal Dystrophies","Color Vision Defects","Macular Degeneration","Achromatopsia","Optical Coherence Tomography (OCT)","Visual Acuity","Genotype","Mutation","Phenotype",[137,138,139,140,141,142],"observational","IRD","ultra low vision","inherited retinal disease","color vision","color test","2025-12-03",{"date":145,"type":48},"2025-12-10",{"date":147,"type":48},"2025-07-20",{"date":149,"type":21},"2027-09-28",{"name":151,"class":55},"Zhongmou Therapeutics",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":124,"phases":4,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":113},"100592376","zhejiang-adolescent-spine-and-vision-health-cohort-a-longitudinal-database-analysis-100592376","NCT06992622","Zhejiang Adolescent Spine and Vision Health Cohort: A Longitudinal Database Analysis","Inclusion Criteria:\n\n* Diagnosis of idiopathic scoliosis at their first clinic visit\n* Skeletally immature (Risser Sign 0-3)\n* Cobb angle between 11-40 degrees\n* Age between 6 and 17\n\nExclusion Criteria:\n\n* • Patients with scoliosis other than idiopathic, or with other musculoskeletal or neurodevelopmental conditions that might be responsible for the scoliosis\n\n  * History of previous spine surgery or spinal injury\n  * Tumor or malignant tumor in the spine\n  * Leg length discrepancy more than 20 mm\n  * Previous diagnosis or treatment of SDB more than 6 months ago\n  * Plans to relocate within the next 24 months","6 Years","17 Years",{"count":161,"type":21},73000,"The aim of study: 1. To investigate the prevalence of scoliosis, other spinal deformities, myopia, and visual impairments in adolescents (aged 6-18) in Zhejiang Province.\n\n2.To track 8-year dynamic changes in spinal curvature and analyze associations between scoliosis, vision disorders, and potential risk factors.\n\n3.To deliver scoliosis health education during screenings.\n\n4.To mitigate scoliosis progression through early detection and intervention.",[164,165,33],"Scoliosis Idiopathic","Myopia",[167,168,169],"Adolescent idiopathic scoliosis","Longitudinal progression","Spine-vision comorbidity","2025-05-19",{"date":172,"type":48},"2025-05-28",{"date":174,"type":48},"2024-09-30",{"date":176,"type":21},"2032-12-30",{"name":178,"class":82},"Second Affiliated Hospital of Wenzhou Medical University",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":186,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":191,"conditions":192,"keywords":202,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":113},"100550753","early-phase-1-novel-antisense-oligonucleotide-eye-drops-for-treating-antibiotic-resistant-bacterial-keratitis-100550753","NCT06451172","Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis","ASOTARI","Inclusion Criteria:\n\n* The results of antimicrobial susceptibility testing in patients with bacterial keratitis showed multidrug-resistant bacterial infections, and the existing commercial antibiotics could not effectively control the disease.\n* Age over 18 years.\n* No systemic immune eye disease.\n* Good eyelid structure and blink function.\n* Exists the potential of visual recovery by evaluation of ocular structure and function.\n* Subjects or their legal guardians voluntarily participate in this study, sign informed consent, good compliance and cooperation with follow-up visits.\n\nExclusion Criteria:\n\n* Lacrimal coating and blink function loss.\n* Schirmer's test result is less than 2mm for severe dry eye disease.\n* Pregnant and lactating women (pregnancy defined in this study as positive urine pregnancy test).\n* Currently is involved in clinical trials of other drugs or medical devices.\n* Active eye infection (including but not limited to: blepharitis, infectious conjunctivitis, sclerotitis, endophthalmitis) in target eye or contralateral eye within 30 days prior to enrollment.\n* Ocular surface malignant tumor.\n* A history of allergic reaction or allergy to sodium luciferin, allergy to protein products used for treatment or diagnosis, allergy to ≥ 2 drugs or non-drug factors, or current allergic disease.\n* current in an infectious disease requiring oral, intramuscular or intravenous administration.\n* Patients with systemic immune diseases.\n* Any uncontrolled clinical problems (such as severe mental, neurological, cardiovascular, respiratory and other systemic diseases and malignant neoplasms).\n* Not effective contraception.\n* In uncontrolled hypertension, systolic is no less than 160 mmhg, diastolic is no less than 100 mmhg.\n* In uncontrolled diabetes, fasting glucose is no less than 10.0umol\u002FL.\n* Renal insufficiency, serum creatinine is more than 133umol\u002FL.\n* Arrhythmia, myocardial ischemia, myocardial infarction (diagnosed by electrocardiogram).\n* Liver dysfunction, al ANINE aminotransferase and aspartate aminotransferase levels are higher than 80 IU\u002FL.\n* Platelet level is below 100,000 \u002FuL or above 450,000 \u002FuL.\n* Hemoglobin level is below 10.0g\u002FdL (male) or 9.0g\u002FdL (female).\n* No anticoagulant was used, prothrombin time is higher than 16s, and thrombin time of activated part is higher than 50s.\n* HIV infection (HIV-positive).\n* Subjects lack compliance with the study or the ability to sign informed consent.\n* There are currently signs of systemic infection, including fever and ongoing antibiotic treatment (in this study, systemic infection was defined as deviation from normal values of white blood cells, lymphocytes, and neutrophils on routine blood tests).\n* Administration of Glucocorticoids and other systemic immunosuppressive drugs.\n* The investigator judges other conditions unsuitable for the trial","18 Years",{"count":188,"type":21},20,[190],"EARLY_PHASE1","The purpose of this study is to evaluate the safety and efficacy of GP-asPNA for in vivo treatment of severe antibiotic resistant bacterial keratitis.",[193,194,195,196,197,33,198,199,200,201],"Bacterial Keratitis","Antibiotic-resistant Bacteria","Infections, Bacterial","Corneal Diseases","Eye Diseases","Sensation Disorders","Blindness","Antisense Peptide Nucleic Acid","Antibacterial Therapy",[193,195,196,197],"2024-06-08",{"date":205,"type":48},"2024-06-11",{"date":207,"type":48},"2023-10-11",{"date":209,"type":21},"2026-10-31",{"name":211,"class":82},"Eye & ENT Hospital of Fudan University"]